by winston » Mon Mar 05, 2012 1:21 pm
not vested
Our take
With the 3 largest contributors (DFI, JC&C and HKL) having reported robust earnings, both JS and JM are likely to report record underlying profit for the year.
We estimate FY11E net underlying profit of US$1.6b for Jardine Strategic, representing core earnings growth of 9%. Jardine Matheson's earnings track Jardine Strategic closely given the cross-holdings between the 2 companies and stakes in similar operating companies.
For FY12E, we are forecasting earnings growth of 12% in net underlying profit to US$1.78b, primarily driven by growth in Astra and Dairy Farm.
At 10.7x FY12E, JS and JM at trading in line with our FY12 P/E of 10-11x for the STI, but both stocks offer superior growth prospects due to their portfolio of resilient businesses, which are generally consumer staples in nature and scalable across its core markets.
Valuation
We use a sum-of-parts valuation to value Jardine Strategic, taking into account the market values of its stakes in its various operating companies. On this basis, JS has a NAV of US$51/share. We apply a discount of 30%, in line with its historical trading range of 30-40% discount to its NAV, to derive a target price of US$36.00.
At current levels, the stock offers a 18% upside to our target price.
Over the past decade, JS's stock has generated total shareholders return of 28% p.a. While repeating this feat over the next decade will be more challenging given the larger base today, we believe future returns will continue to be satisfactory given the group's portfolio of outstanding businesses and strong management.
Source: DMG
It's all about "how much you made when you were right" & "how little you lost when you were wrong"